Literature DB >> 11196270

Secondary myelodysplasia with monosomy 7 arising after treatment for acute lymphoblastic leukemia in childhood.

V M Aquino1, N R Schneider, E S Sandler.   

Abstract

Monosomy 7 is recognized as a characteristic, clonal abnormality associated with acquired myelodysplasia (MDS) or acute myeloid leukemia (AML). It can occur as a late complication of cytotoxic therapy and is usually associated with exposure to alkylating agents or radiation therapy. We report two patients with therapy-related myelodysplasia (t-MDS) associated with monosomy 7 occurring in children after completion of therapy for acute lymphoblastic leukemia (ALL). Both children were noted to have t-MDS with monosomy 7 at the time of cessation of chemotherapy. Neither child had received an alkylating agent or radiation therapy during treatment. One child had a unique dicentric marker chromosome that was shown by fluorescent in situ hybridization to be derived from chromosome 7. This report emphasizes the need to identify and minimize therapy-related side effects without compromising cure rates.

Entities:  

Mesh:

Year:  2001        PMID: 11196270     DOI: 10.1097/00043426-200101000-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia.

Authors:  Masahiro Masuya; Naoyuki Katayama; Koichi Inagaki; Hiroshi Miwa; Natsuki Hoshino; Hiroyuki Miyashita; Hirohito Suzuki; Hiroto Araki; Hidetsugu Mitani; Kazuhiro Nishii; Shin-ichi Kageyama; Nobuyuki Minami; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

2.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Authors:  Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta
Journal:  Blood       Date:  2007-04-18       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.